Areas of Expertise

Dr John Ferguson performs a range of treatments including:

• Photodermatology
• Phototherapy

Some of the conditions he commonly treats are:

• General Dermatology
• Skin Cancer
• Vitiligo
• Psoriasis
• Eczema
• Acne

About Dr John Ferguson

Dr John Ferguson is a Consultant Dermatologist who specialises in general dermatology, skin cancer and vitiligo. He has published work on a variety of dermatological subjects including Skin Cancer and Photodermatology. He has given presentations both nationally and internationally on a variety of topics.

After qualifying as a doctor from Bristol University in 2005, Dr Ferguson completed training in the UK at St George’s Hospital in London and internationally at The Skin and Cancer Foundation in Melbourne.

Dr Ferguson works as a Consultant Dermatologist at The St John’s Institute of Dermatology at Guy’s and St Thomas’ Hospital. He offers a general clinic and specialist clinics in vitiligo, photodermatology and phototherapy. He is the clinical lead for Phototherapy and Vitiligo at St John’s.

Dr Ferguson has published work on a variety of dermatological subjects including Skin Cancer and Photodermatology. He has given presentations both nationally and internationally on a variety of topics.Recognised by all major UK health insurers, Dr Ferguson sees adults and teenage children primarily, but will also see younger children with problems arising within his areas of special interest.

Research Highlights

Dr John Ferguson has achieved multiple publications:

Key Publications

• Ferguson JS. “Photodermatology” ABC of Dermatology, Seventh Edition. Edited by Rachael Morris-Jones. John Wiley & Sons (Awaiting publication)2018
• Ho, Bernard, Natasha Howard, Sandra Howard, Andrea Cochrane, John Ferguson, and Sally Ibbotson. 2020. “A Photodynamic Therapy Patient Survey: Real-Life Experience from Two Regional Services.” Photodermatology, Photoimmunology & Photomedicine, December. https://doi.org/10.1111/phpp.12638
• Cotter, C., and J. Ferguson. 2020. “‘Ruxolitinib Cream for the Treatment of Vitiligo: A Randomised, Controlled, Phase 2 Trial’: A Critical Appraisal.” The British Journal of Dermatology, November.